<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04308668</url>
  </required_header>
  <id_info>
    <org_study_id>MED-2020-28673</org_study_id>
    <nct_id>NCT04308668</nct_id>
  </id_info>
  <brief_title>Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2</brief_title>
  <acronym>COVID-19 PEP</acronym>
  <official_title>Post-exposure Prophylaxis or Preemptive Therapy for SARS-Coronavirus-2: A Pragmatic Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>McGill University Health Centre/Research Institute of the McGill University Health Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Manitoba</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Alberta</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Minnesota</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study Objective:&#xD;
&#xD;
        1. To test if post-exposure prophylaxis with hydroxychloroquine can prevent symptomatic&#xD;
           COVID-19 disease after known exposure to the SARS-CoV-2 coronavirus.&#xD;
&#xD;
        2. To test if early preemptive hydroxychloroquine therapy can prevent disease progression&#xD;
           in persons with known symptomatic COVID-19 disease, decreasing hospitalizations and&#xD;
           symptom severity.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a rapidly emerging viral&#xD;
      infection causing COVID19. The current strategy uses a public health model of identifying&#xD;
      infected cases, isolation, and quarantine to stop transmission. Once exposed, observation is&#xD;
      standard-of-care. Therapy is generally not given to persons who are not hospitalized. The&#xD;
      doses of hydroxychloroquine being used are within the normal standard FDA-approved doses.&#xD;
&#xD;
      Hydroxychloroquine may have antiviral effects against SARS-COV2 which may prevent COVID-19&#xD;
      disease or early preemptive therapy may decrease disease severity. This trial will use a&#xD;
      modification of standard malaria dosing of hydroxychloroquine to provide post-exposure&#xD;
      prophylaxis to prevent disease or preemptive therapy for those with early symptoms. People&#xD;
      around the the United States and Canada can participate to help answer this critically&#xD;
      important question. No in-person visits are needed.&#xD;
&#xD;
      This trial is targeting 5 groups of people NATIONWIDE to participate:&#xD;
&#xD;
        1. If you are symptomatic with a positive COVID-19 test within the first 4 days of symptoms&#xD;
           and are not hospitalized; OR&#xD;
&#xD;
        2. If you live with someone who has been diagnosed with COVID-19, with your last exposure&#xD;
           within the last 4 days, and do not have any symptoms; OR&#xD;
&#xD;
        3. If you live with someone who has been diagnosed with COVID-19, and your symptoms started&#xD;
           within the last 4 days; OR&#xD;
&#xD;
        4. If you have had occupational exposure with known exposure to someone with lab-confirmed&#xD;
           COVID-19 within the last 4 days and do not have symptoms; OR&#xD;
&#xD;
        5. If you have had occupational exposure with known exposure to someone with lab-confirmed&#xD;
           COVID-19 within the last 4 days AND have compatible symptoms starting within the last 4&#xD;
           days;&#xD;
&#xD;
      You may participate if you live anywhere in the United States (including territories) or in&#xD;
      the Canadian Provinces of Quebec, Manitoba, Alberta, or Ontario.&#xD;
&#xD;
      For information on how to participate in the research trial, go to covidpep.umn.edu or email&#xD;
      covid19@umn.edu for instructions. Please check your spam folder if you email.&#xD;
&#xD;
      In Canada, for trial information, please go to: www.covid-19research.ca&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 17, 2020</start_date>
  <completion_date type="Actual">May 20, 2020</completion_date>
  <primary_completion_date type="Actual">May 20, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Asymptomatic participants are randomized and analyzed separate from symptomatic participants.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Active COVID-19 Disease at Day 14 Among Those Who Were Asymptomatic at Baseline</measure>
    <time_frame>14 days</time_frame>
    <description>Number of participants at 14 days post enrollment with active COVID19 disease among those who were asymptomatic at baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Disease Severity Over 14 Days Among Those Who Are Symptomatic at Baseline</measure>
    <time_frame>baseline and 14 days</time_frame>
    <description>Visual Analog Scale 0-10 score of rating overall symptom severity (0 = no symptoms; 10 = most severe)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of Hospitalization</measure>
    <time_frame>14 days</time_frame>
    <description>Outcome reported as the number of participants in each arm who require hospitalization for COVID19-related disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Death</measure>
    <time_frame>Approximately 30 days</time_frame>
    <description>Outcome reported as the number of participants in each arm who expire due to COVID-19-related disease through study completion of 14 days. For those hospitalized within the 14-day study period, the protocol specified follow up would occur for up to 90 days to capture the final outcome of participants' hospitalization. Approximately 30-days was the maximal follow up for hospitalization outcome needed in the trial.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Confirmed SARS-CoV-2 Detection</measure>
    <time_frame>14 days</time_frame>
    <description>Outcome reported as the number of participants in each arm who have confirmed SARS-CoV-2 infection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Symptoms Compatible With COVID-19 (Possible Disease)</measure>
    <time_frame>14 days</time_frame>
    <description>Outcome reported as the number of participants in each arm who self-report symptoms compatible with COVID-19 infection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of All-Cause Study Medicine Discontinuation or Withdrawal</measure>
    <time_frame>14 days</time_frame>
    <description>Outcome reported as the number of participants in each arm who discontinue or withdraw medication use for any reason.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Symptom Severity at 5 and 14 Days</measure>
    <time_frame>5 and 14 days</time_frame>
    <description>Visual Analog Scale 0-10 score of rating overall symptom severity (0 = no symptoms; 10 = most severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Severe COVID-19 Disease at 14 Days Among Those Who Are Symptomatic at Trial Entry</measure>
    <time_frame>14 days</time_frame>
    <description>Participants will self-report disease severity status as one of the following 3 options; no COVID19 illness (score of 1), COVID19 illness with no hospitalization (score of 2), or COVID19 illness with hospitalization or death (score of 3). Increased scale score indicates greater disease severity. Outcome is reported as the number of participants who report a score of 3.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1312</enrollment>
  <condition>Corona Virus Infection</condition>
  <condition>Acute Respiratory Distress Syndrome</condition>
  <condition>SARS-CoV Infection</condition>
  <condition>Coronavirus</condition>
  <condition>Coronavirus Infections</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this arm will receive the study drug.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants in this arm will receive a placebo treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine</intervention_name>
    <description>200mg tablet; 800 mg orally once, followed in 6 to 8 hours by 600 mg, then 600mg once a day for 4 consecutive days</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Plaquenil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>4 placebo tablets once, followed in 6 to 8 hours by 3 tablets, then 3 tablets once-a-day for 4 consecutive days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Provision of informed consent&#xD;
&#xD;
          -  Exposure to a COVID19 case within 4 days as either a household contact or occupational&#xD;
             exposure, OR&#xD;
&#xD;
          -  Symptomatic COVID19 case with confirmed diagnosis within 4 days of symptom onset OR&#xD;
             symptomatic high risk exposure with known COVID19 contact and within 4 days of symptom&#xD;
             onset;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current hospitalization&#xD;
&#xD;
          -  Allergy to hydroxychloroquine&#xD;
&#xD;
          -  Retinal eye disease&#xD;
&#xD;
          -  Known glucose-6 phosphate dehydrogenase (G-6-PD) deficiency&#xD;
&#xD;
          -  Known chronic kidney disease, stage 4 or 5 or receiving dialysis&#xD;
&#xD;
          -  Structural or ischemic heart disease&#xD;
&#xD;
          -  Personal or Family History of Prolonged QT syndrome&#xD;
&#xD;
          -  Weight &lt; 50 kg&#xD;
&#xD;
          -  Known Porphyria&#xD;
&#xD;
          -  Current use of: hydroxychloroquine or cardiac medicines of: flecainide, Tambocor;&#xD;
             amiodarone, Cordarone, Pacerone; digoxin or Digox, Digitek, Lanoxin; procainamide or&#xD;
             Procan, Procanbid, propafenone, Rythmal, sotalol;&#xD;
&#xD;
          -  Current use of medicines which prolong the QT interval including:&#xD;
&#xD;
               -  Antimicrobials: levofloxacin, ciprofloxacin, moxifloxacin, azithromycin,&#xD;
                  clarithromycin, erythromycin, ketoconazole, itraconazole, or mefloquine&#xD;
&#xD;
               -  Antidepressants: amitriptyline, citalopram, desipramine, escitalopram,&#xD;
                  imipramine, doxepin, fluoxetine, wellbutrin, or venlafaxine&#xD;
&#xD;
               -  Antipsychotic or mood stabilizers: haloperidol, droperidol, lithium, quetiapine,&#xD;
                  thioridazine, ziprasidone&#xD;
&#xD;
               -  Methadone&#xD;
&#xD;
               -  Sumatriptan, zolmitriptan&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Boulware, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nationwide Enrollment via Internet, please email: covid19@umn.edu</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Institute of the McGill University Heath Centre</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Lother SA, Abassi M, Agostinis A, Bangdiwala AS, Cheng MP, Drobot G, Engen N, Hullsiek KH, Kelly LE, Lee TC, Lofgren SM, MacKenzie LJ, Marten N, McDonald EG, Okafor EC, Pastick KA, Pullen MF, Rajasingham R, Schwartz I, Skipper CP, Turgeon AF, Zarychanski R, Boulware DR. Post-exposure prophylaxis or pre-emptive therapy for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): study protocol for a pragmatic randomized-controlled trial. Can J Anaesth. 2020 Sep;67(9):1201-1211. doi: 10.1007/s12630-020-01684-7. Epub 2020 May 7.</citation>
    <PMID>32383125</PMID>
  </reference>
  <reference>
    <citation>Pastick KA, Okafor EC, Wang F, Lofgren SM, Skipper CP, Nicol MR, Pullen MF, Rajasingham R, McDonald EG, Lee TC, Schwartz IS, Kelly LE, Lother SA, Mitjà O, Letang E, Abassi M, Boulware DR. Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19). Open Forum Infect Dis. 2020 Apr 15;7(4):ofaa130. doi: 10.1093/ofid/ofaa130. eCollection 2020 Apr. Review.</citation>
    <PMID>32363212</PMID>
  </reference>
  <reference>
    <citation>Al-Kofahi M, Jacobson P, Boulware DR, Matas A, Kandaswamy R, Jaber MM, Rajasingham R, Young JH, Nicol MR. Finding the Dose for Hydroxychloroquine Prophylaxis for COVID-19: The Desperate Search for Effectiveness. Clin Pharmacol Ther. 2020 Oct;108(4):766-769. doi: 10.1002/cpt.1874. Epub 2020 Jun 1.</citation>
    <PMID>32344449</PMID>
  </reference>
  <reference>
    <citation>Ingraham NE, Boulware D, Sparks MA, Schacker T, Benson B, Sparks JA, Murray T, Connett J, Chipman JG, Charles A, Tignanelli CJ. Shining a light on the evidence for hydroxychloroquine in SARS-CoV-2. Crit Care. 2020 Apr 28;24(1):182. doi: 10.1186/s13054-020-02894-7.</citation>
    <PMID>32345336</PMID>
  </reference>
  <reference>
    <citation>Pullen MF, Pastick KA, Williams DA, Nascene AA, Bangdiwala AS, Okafor EC, Hullsiek KH, Skipper CP, Lofgren SM, Engen N, Abassi M, McDonald EG, Lee TC, Rajasingham R, Boulware DR. Lessons Learned From Conducting Internet-Based Randomized Clinical Trials During a Global Pandemic. Open Forum Infect Dis. 2020 Dec 28;8(2):ofaa602. doi: 10.1093/ofid/ofaa602. eCollection 2021 Feb. Review.</citation>
    <PMID>33553471</PMID>
  </reference>
  <reference>
    <citation>Okafor EC, Pastick KA, Rajasingham R. Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. Reply. N Engl J Med. 2020 Sep 10;383(11):1089. doi: 10.1056/NEJMc2023617. Epub 2020 Jul 15.</citation>
    <PMID>32668109</PMID>
  </reference>
  <results_reference>
    <citation>Boulware DR, Pullen MF, Bangdiwala AS, Pastick KA, Lofgren SM, Okafor EC, Skipper CP, Nascene AA, Nicol MR, Abassi M, Engen NW, Cheng MP, LaBar D, Lother SA, MacKenzie LJ, Drobot G, Marten N, Zarychanski R, Kelly LE, Schwartz IS, McDonald EG, Rajasingham R, Lee TC, Hullsiek KH. A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. N Engl J Med. 2020 Aug 6;383(6):517-525. doi: 10.1056/NEJMoa2016638. Epub 2020 Jun 3.</citation>
    <PMID>32492293</PMID>
  </results_reference>
  <results_reference>
    <citation>Skipper CP, Pastick KA, Engen NW, Bangdiwala AS, Abassi M, Lofgren SM, Williams DA, Okafor EC, Pullen MF, Nicol MR, Nascene AA, Hullsiek KH, Cheng MP, Luke D, Lother SA, MacKenzie LJ, Drobot G, Kelly LE, Schwartz IS, Zarychanski R, McDonald EG, Lee TC, Rajasingham R, Boulware DR. Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19 : A Randomized Trial. Ann Intern Med. 2020 Oct 20;173(8):623-631. doi: 10.7326/M20-4207. Epub 2020 Jul 16. Erratum in: Ann Intern Med. 2021 Mar;174(3):435.</citation>
    <PMID>32673060</PMID>
  </results_reference>
  <results_reference>
    <citation>Lofgren SM, Nicol MR, Bangdiwala AS, Pastick KA, Okafor EC, Skipper CP, Pullen MF, Engen NW, Abassi M, Williams DA, Nascene AA, Axelrod ML, Lother SA, MacKenzie LJ, Drobot G, Marten N, Cheng MP, Zarychanski R, Schwartz IS, Silverman M, Chagla Z, Kelly LE, McDonald EG, Lee TC, Hullsiek KH, Boulware DR, Rajasingham R. Safety of Hydroxychloroquine Among Outpatient Clinical Trial Participants for COVID-19. Open Forum Infect Dis. 2020 Oct 19;7(11):ofaa500. doi: 10.1093/ofid/ofaa500. eCollection 2020 Nov.</citation>
    <PMID>33204764</PMID>
  </results_reference>
  <results_reference>
    <citation>Skipper CP, Boulware DR. Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19. Ann Intern Med. 2021 Mar;174(3):434-435. doi: 10.7326/L20-1426.</citation>
    <PMID>33721539</PMID>
  </results_reference>
  <results_reference>
    <citation>Nicol MR, Boulware DR, Rajasingham R. Reply to Neves. Clin Infect Dis. 2021 Oct 5;73(7):e1772-e1774. doi: 10.1093/cid/ciaa1809.</citation>
    <PMID>33274360</PMID>
  </results_reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>March 11, 2020</study_first_submitted>
  <study_first_submitted_qc>March 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2020</study_first_posted>
  <results_first_submitted>April 26, 2021</results_first_submitted>
  <results_first_submitted_qc>May 11, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 13, 2021</results_first_posted>
  <last_update_submitted>May 11, 2021</last_update_submitted>
  <last_update_submitted_qc>May 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>Corona Virus</keyword>
  <keyword>SARS-COV-2</keyword>
  <keyword>Coronavirus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Respiratory Distress Syndrome</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxychloroquine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified dataset will be available within 1 month of publication.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>at time of publication</ipd_time_frame>
    <ipd_access_criteria>To be publicly provided. Please register at the website to receive the dataset.</ipd_access_criteria>
    <ipd_url>https://covidpep.umn.edu/data</ipd_url>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>http://www.covidpep.umn.edu/data</doc_url>
    </study_doc>
  </study_docs>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 24, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/68/NCT04308668/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 24, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/68/NCT04308668/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment</title>
          <description>Participants in this arm will receive the study drug.&#xD;
Hydroxychloroquine: 200mg tablet; 800 mg orally once, followed in 6 to 8 hours by 600 mg, then 600mg once a day for 4 consecutive days</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Participants in this arm will receive a placebo treatment.&#xD;
Placebo: 4 placebo tablets once, followed in 6 to 8 hours by 3 tablets, then 3 tablets once-a-day for 4 consecutive days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="658"/>
                <participants group_id="P2" count="654"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="622"/>
                <participants group_id="P2" count="612"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="42"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="38"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment</title>
          <description>Participants in this arm will receive the study drug.&#xD;
Hydroxychloroquine: 200mg tablet; 800 mg orally once, followed in 6 to 8 hours by 600 mg, then 600mg once a day for 4 consecutive days</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Participants in this arm will receive a placebo treatment.&#xD;
Placebo: 4 placebo tablets once, followed in 6 to 8 hours by 3 tablets, then 3 tablets once-a-day for 4 consecutive days</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="658"/>
            <count group_id="B2" value="654"/>
            <count group_id="B3" value="1312"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="658"/>
                    <count group_id="B2" value="654"/>
                    <count group_id="B3" value="1312"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42" spread="12"/>
                    <measurement group_id="B2" value="42" spread="12"/>
                    <measurement group_id="B3" value="42" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>While biological sex at birth was the question, 4 persons in each arm did not identify as male or female.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Sex</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="654"/>
                    <count group_id="B2" value="650"/>
                    <count group_id="B3" value="1304"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="354"/>
                    <measurement group_id="B2" value="336"/>
                    <measurement group_id="B3" value="690"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="300"/>
                    <measurement group_id="B2" value="314"/>
                    <measurement group_id="B3" value="614"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-binary</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="4"/>
                    <count group_id="B2" value="4"/>
                    <count group_id="B3" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <description>Participants could identify as more than one Race/Ethnicity</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="658"/>
                    <count group_id="B2" value="654"/>
                    <count group_id="B3" value="1312"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian/South Asian</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="658"/>
                    <count group_id="B2" value="654"/>
                    <count group_id="B3" value="1312"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="204"/>
                    <measurement group_id="B2" value="206"/>
                    <measurement group_id="B3" value="410"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Pacific Islander</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="658"/>
                    <count group_id="B2" value="654"/>
                    <count group_id="B3" value="1312"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="658"/>
                    <count group_id="B2" value="654"/>
                    <count group_id="B3" value="1312"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="658"/>
                    <count group_id="B2" value="654"/>
                    <count group_id="B3" value="1312"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="363"/>
                    <measurement group_id="B2" value="379"/>
                    <measurement group_id="B3" value="742"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic or Latino</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="658"/>
                    <count group_id="B2" value="654"/>
                    <count group_id="B3" value="1312"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Middle Eastern</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="658"/>
                    <count group_id="B2" value="654"/>
                    <count group_id="B3" value="1312"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown/Not Reported</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="658"/>
                    <count group_id="B2" value="654"/>
                    <count group_id="B3" value="1312"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Canada</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="658"/>
                    <count group_id="B2" value="654"/>
                    <count group_id="B3" value="1312"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="658"/>
                    <count group_id="B2" value="654"/>
                    <count group_id="B3" value="1312"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="628"/>
                    <measurement group_id="B2" value="625"/>
                    <measurement group_id="B3" value="1253"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Active COVID-19 Disease at Day 14 Among Those Who Were Asymptomatic at Baseline</title>
        <description>Number of participants at 14 days post enrollment with active COVID19 disease among those who were asymptomatic at baseline.</description>
        <time_frame>14 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Participants in this arm will receive the study drug.&#xD;
Hydroxychloroquine: 200mg tablet; 800 mg orally once, followed in 6 to 8 hours by 600 mg, then 600mg once a day for 4 consecutive days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants in this arm will receive a placebo treatment.&#xD;
Placebo: 4 placebo tablets once, followed in 6 to 8 hours by 3 tablets, then 3 tablets once-a-day for 4 consecutive days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Active COVID-19 Disease at Day 14 Among Those Who Were Asymptomatic at Baseline</title>
          <description>Number of participants at 14 days post enrollment with active COVID19 disease among those who were asymptomatic at baseline.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="414"/>
                <count group_id="O2" value="407"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.35</p_value>
            <method>Fisher Exact</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-2.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.0</ci_lower_limit>
            <ci_upper_limit>2.2</ci_upper_limit>
            <estimate_desc>Values represent percentages. Experimental treatment arm compared with the placebo control arm.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Disease Severity Over 14 Days Among Those Who Are Symptomatic at Baseline</title>
        <description>Visual Analog Scale 0-10 score of rating overall symptom severity (0 = no symptoms; 10 = most severe)</description>
        <time_frame>baseline and 14 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Participants in this arm will receive the study drug.&#xD;
Hydroxychloroquine: 200mg tablet; 800 mg orally once, followed in 6 to 8 hours by 600 mg, then 600mg once a day for 4 consecutive days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants in this arm will receive a placebo treatment.&#xD;
Placebo: 4 placebo tablets once, followed in 6 to 8 hours by 3 tablets, then 3 tablets once-a-day for 4 consecutive days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Disease Severity Over 14 Days Among Those Who Are Symptomatic at Baseline</title>
          <description>Visual Analog Scale 0-10 score of rating overall symptom severity (0 = no symptoms; 10 = most severe)</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="212"/>
                <count group_id="O2" value="211"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.6" spread=".12"/>
                    <measurement group_id="O2" value="-2.33" spread=".12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.117</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.27</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.61</ci_lower_limit>
            <ci_upper_limit>0.27</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Hospitalization</title>
        <description>Outcome reported as the number of participants in each arm who require hospitalization for COVID19-related disease.</description>
        <time_frame>14 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Participants in this arm will receive the study drug.&#xD;
Hydroxychloroquine: 200mg tablet; 800 mg orally once, followed in 6 to 8 hours by 600 mg, then 600mg once a day for 4 consecutive days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants in this arm will receive a placebo treatment.&#xD;
Placebo: 4 placebo tablets once, followed in 6 to 8 hours by 3 tablets, then 3 tablets once-a-day for 4 consecutive days</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Hospitalization</title>
          <description>Outcome reported as the number of participants in each arm who require hospitalization for COVID19-related disease.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="645"/>
                <count group_id="O2" value="641"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Death</title>
        <description>Outcome reported as the number of participants in each arm who expire due to COVID-19-related disease through study completion of 14 days. For those hospitalized within the 14-day study period, the protocol specified follow up would occur for up to 90 days to capture the final outcome of participants' hospitalization. Approximately 30-days was the maximal follow up for hospitalization outcome needed in the trial.</description>
        <time_frame>Approximately 30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Participants in this arm will receive the study drug.&#xD;
Hydroxychloroquine: 200mg tablet; 800 mg orally once, followed in 6 to 8 hours by 600 mg, then 600mg once a day for 4 consecutive days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants in this arm will receive a placebo treatment.&#xD;
Placebo: 4 placebo tablets once, followed in 6 to 8 hours by 3 tablets, then 3 tablets once-a-day for 4 consecutive days</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Death</title>
          <description>Outcome reported as the number of participants in each arm who expire due to COVID-19-related disease through study completion of 14 days. For those hospitalized within the 14-day study period, the protocol specified follow up would occur for up to 90 days to capture the final outcome of participants' hospitalization. Approximately 30-days was the maximal follow up for hospitalization outcome needed in the trial.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="645"/>
                <count group_id="O2" value="641"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Confirmed SARS-CoV-2 Detection</title>
        <description>Outcome reported as the number of participants in each arm who have confirmed SARS-CoV-2 infection.</description>
        <time_frame>14 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Participants in this arm will receive the study drug.&#xD;
Hydroxychloroquine: 200mg tablet; 800 mg orally once, followed in 6 to 8 hours by 600 mg, then 600mg once a day for 4 consecutive days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants in this arm will receive a placebo treatment.&#xD;
Placebo: 4 placebo tablets once, followed in 6 to 8 hours by 3 tablets, then 3 tablets once-a-day for 4 consecutive days</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Confirmed SARS-CoV-2 Detection</title>
          <description>Outcome reported as the number of participants in each arm who have confirmed SARS-CoV-2 infection.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="414"/>
                <count group_id="O2" value="407"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Occurrence of Symptoms Compatible With COVID-19 (Possible Disease)</title>
        <description>Outcome reported as the number of participants in each arm who self-report symptoms compatible with COVID-19 infection.</description>
        <time_frame>14 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Participants in this arm will receive the study drug.&#xD;
Hydroxychloroquine: 200mg tablet; 800 mg orally once, followed in 6 to 8 hours by 600 mg, then 600mg once a day for 4 consecutive days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants in this arm will receive a placebo treatment.&#xD;
Placebo: 4 placebo tablets once, followed in 6 to 8 hours by 3 tablets, then 3 tablets once-a-day for 4 consecutive days</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Symptoms Compatible With COVID-19 (Possible Disease)</title>
          <description>Outcome reported as the number of participants in each arm who self-report symptoms compatible with COVID-19 infection.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="414"/>
                <count group_id="O2" value="407"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of All-Cause Study Medicine Discontinuation or Withdrawal</title>
        <description>Outcome reported as the number of participants in each arm who discontinue or withdraw medication use for any reason.</description>
        <time_frame>14 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Participants in this arm will receive the study drug.&#xD;
Hydroxychloroquine: 200mg tablet; 800 mg orally once, followed in 6 to 8 hours by 600 mg, then 600mg once a day for 4 consecutive days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants in this arm will receive a placebo treatment.&#xD;
Placebo: 4 placebo tablets once, followed in 6 to 8 hours by 3 tablets, then 3 tablets once-a-day for 4 consecutive days</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of All-Cause Study Medicine Discontinuation or Withdrawal</title>
          <description>Outcome reported as the number of participants in each arm who discontinue or withdraw medication use for any reason.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="645"/>
                <count group_id="O2" value="641"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97"/>
                    <measurement group_id="O2" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Symptom Severity at 5 and 14 Days</title>
        <description>Visual Analog Scale 0-10 score of rating overall symptom severity (0 = no symptoms; 10 = most severe)</description>
        <time_frame>5 and 14 days</time_frame>
        <population>Early preemptive treatment trial (n=423 symptomatic participants with data)</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Participants in this arm will receive the study drug.&#xD;
Hydroxychloroquine: 200mg tablet; 800 mg orally once, followed in 6 to 8 hours by 600 mg, then 600mg once a day for 4 consecutive days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants in this arm will receive a placebo treatment.&#xD;
Placebo: 4 placebo tablets once, followed in 6 to 8 hours by 3 tablets, then 3 tablets once-a-day for 4 consecutive days</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Symptom Severity at 5 and 14 Days</title>
          <description>Visual Analog Scale 0-10 score of rating overall symptom severity (0 = no symptoms; 10 = most severe)</description>
          <population>Early preemptive treatment trial (n=423 symptomatic participants with data)</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="212"/>
                <count group_id="O2" value="211"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.22" lower_limit="-2.53" upper_limit="-1.9"/>
                    <measurement group_id="O2" value="-2.05" lower_limit="-2.37" upper_limit="-1.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.36" lower_limit="-3.62" upper_limit="-3.09"/>
                    <measurement group_id="O2" value="-3.08" lower_limit="-3.35" upper_limit="-2.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Severe COVID-19 Disease at 14 Days Among Those Who Are Symptomatic at Trial Entry</title>
        <description>Participants will self-report disease severity status as one of the following 3 options; no COVID19 illness (score of 1), COVID19 illness with no hospitalization (score of 2), or COVID19 illness with hospitalization or death (score of 3). Increased scale score indicates greater disease severity. Outcome is reported as the number of participants who report a score of 3.</description>
        <time_frame>14 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Participants in this arm will receive the study drug.&#xD;
Hydroxychloroquine: 200mg tablet; 800 mg orally once, followed in 6 to 8 hours by 600 mg, then 600mg once a day for 4 consecutive days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants in this arm will receive a placebo treatment.&#xD;
Placebo: 4 placebo tablets once, followed in 6 to 8 hours by 3 tablets, then 3 tablets once-a-day for 4 consecutive days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Severe COVID-19 Disease at 14 Days Among Those Who Are Symptomatic at Trial Entry</title>
          <description>Participants will self-report disease severity status as one of the following 3 options; no COVID19 illness (score of 1), COVID19 illness with no hospitalization (score of 2), or COVID19 illness with hospitalization or death (score of 3). Increased scale score indicates greater disease severity. Outcome is reported as the number of participants who report a score of 3.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="231"/>
                <count group_id="O2" value="234"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Approximately 30-days</time_frame>
      <desc>Reporting period was for onset of adverse events within 14 days. All hospitalizations were followed for up to 90 days for final resolution of outcome. Approximately 30 days was the maximal duration needed to capture final outcome.</desc>
      <group_list>
        <group group_id="E1">
          <title>Treatment</title>
          <description>Participants in this arm will receive the study drug.&#xD;
Hydroxychloroquine: 200mg tablet; 800 mg orally once, followed in 6 to 8 hours by 600 mg, then 600mg once a day for 4 consecutive days</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Participants in this arm will receive a placebo treatment.&#xD;
Placebo: 4 placebo tablets once, followed in 6 to 8 hours by 3 tablets, then 3 tablets once-a-day for 4 consecutive days</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="658"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="654"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="658"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="654"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalizations not related to COVID or study medicine</sub_title>
                <description>Adjudication was conducted by blinded investigators.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="658"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="654"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>COVID-related hospitalization</sub_title>
                <description>n=5 vs. n=8 hospitalizations in early treatment population, n=1 vs. n=1 hospitalizations in postexposure prophylaxis population</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="658"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="654"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="367" subjects_at_risk="658"/>
                <counts group_id="E2" subjects_affected="148" subjects_at_risk="654"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="658"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="654"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Visual changes</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="658"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="654"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea or upset stomach</sub_title>
                <counts group_id="E1" events="146" subjects_affected="146" subjects_at_risk="658"/>
                <counts group_id="E2" events="53" subjects_affected="53" subjects_at_risk="654"/>
              </event>
              <event>
                <sub_title>Diarrhea, abdominal pain, vomiting</sub_title>
                <counts group_id="E1" events="131" subjects_affected="131" subjects_at_risk="658"/>
                <counts group_id="E2" events="35" subjects_affected="35" subjects_at_risk="654"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Irritability, dizziness, vertigo</sub_title>
                <counts group_id="E1" events="39" subjects_affected="39" subjects_at_risk="658"/>
                <counts group_id="E2" events="26" subjects_affected="26" subjects_at_risk="654"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="658"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="654"/>
              </event>
              <event>
                <sub_title>Taste change or dry mouth</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="658"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="654"/>
              </event>
              <event>
                <sub_title>Hot flashes, night sweats, palpitations</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="658"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="654"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="658"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="654"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="658"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="654"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction (non-anaphylaxis)</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="658"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="654"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Panic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="658"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="654"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin reaction</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="658"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="654"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>David Boulware, MD, MPH</name_or_title>
      <organization>University of Minnesota</organization>
      <phone>6125552020</phone>
      <email>covid19@umn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

